Amgen's 2025 financials rebounded strongly with diluted EPS of $14.23 on revenue of $36.7B, yet the stock has corrected 13% in three months and now trades at 23.5x earnings—a modest premium to peers. While smart money accumulation (score +0.12) and a maturing pipeline (16 potential blockbusters including MariTide) offer upside, a DCF-derived fair value near $292 and recent Tavneos safety concerns in Japan limit near-term conviction. We see the risk/reward as balanced and await clearer evidence that top-line growth can offset looming patent cliffs and pricing pressure.
LOE exposure
Legacy products like Enbrel face biosimilar erosion, which could pressure revenues faster than new launches can compensate.
Pipeline execution
Failure of key assets (e.g., MariTide in obesity) or clinical setbacks in the 16 pipeline candidates would undermine the growth narrative.
Japan safety overhang
Tavneos was linked to 20 deaths and liver injuries in Japan; while restrictions were partially lifted, any additional safety signal could lead to market withdrawal or liabilities.
Valuation compression
At a P/E above the peer median, the stock could de-rate if earnings growth decelerates or the market re-rates pharma lower.